Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease

Phase 2

Completed

Conditions: Hodgkin Disease
Hodgkin's Lymphoma
Lymphoma

Interventions: Drug: Gemcitabine
Drug: Vinorelbine
Drug: Carmustine
Drug: Etoposide
Drug: Cyclophosphamide
Procedure: Autologous HCT

First Posted Date: 2006-10-16

Last Posted Date: 2017-06-14

Lead Sponsor: Stanford University

Target Recruit Count: 146

Registration Number: NCT00388349

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: umbilical cord blood transplantation
Radiation: total-body irradiation

First Posted Date: 2006-10-13

Last Posted Date: 2016-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT00387959

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Phase 3

Completed

Conditions: L2 Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia in Remission
L1 Childhood Acute Lymphoblastic Leukemia
Graft Versus Host Disease
T-cell Childhood Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: thiotepa
Drug: cyclophosphamide
Drug: tacrolimus
Drug: methotrexate
Drug: sirolimus
Radiation: total body irradiation

First Posted Date: 2006-09-28

Last Posted Date: 2019-08-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 146

Registration Number: NCT00382109

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

and more 47 locations

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: L1 Childhood Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: vincristine sulfate
Drug: prednisone
Drug: doxorubicin hydrochloride
Drug: pegaspargase
Drug: cytarabine
Drug: methotrexate
Drug: dexamethasone
Drug: etoposide
Drug: cyclophosphamide
Drug: leucovorin calcium
Biological: filgrastim
Drug: asparaginase
Drug: mercaptopurine

First Posted Date: 2006-09-28

Last Posted Date: 2024-03-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 275

Registration Number: NCT00381680

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸
Childrens Memorial Hospital, Chicago, Illinois, United States

and more 170 locations

FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Sargramostim
Drug: Rituximab

First Posted Date: 2006-09-27

Last Posted Date: 2016-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00381004

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Phase 1

Completed

Conditions: Lymphoma, Large-Cell, Diffuse
Lymphoma, B-Cell

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
Drug: Lenograstim

First Posted Date: 2006-09-22

Last Posted Date: 2013-03-15

Lead Sponsor: Asan Medical Center

Target Recruit Count: 49

Registration Number: NCT00379574

Locations: 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
🇰🇷
Asan Medical Cener, Seoul, Korea, Republic of

Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

Phase 3

Conditions: Sarcoma

First Posted Date: 2006-09-21

Last Posted Date: 2013-08-12

Lead Sponsor: European Paediatric Soft Tissue Sarcoma Study Group

Target Recruit Count: 600

Registration Number: NCT00379457

Locations: 🇸🇪
Uppsala University Hospital, Uppsala, Sweden
🇩🇰
Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
🇮🇪
Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland

and more 23 locations

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Phase 3

Active, not recruiting

Conditions: Stage III Kidney Wilms Tumor
Stage IV Kidney Wilms Tumor

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Conventional Surgery
Drug: Cyclophosphamide
Biological: Dactinomycin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Vincristine Sulfate Liposome

First Posted Date: 2006-09-21

Last Posted Date: 2024-04-16

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 395

Registration Number: NCT00379340

Locations: 🇺🇸
Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States

and more 224 locations

Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: cyclophosphamide
Drug: docetaxel
Drug: epirubicin hydrochloride
Procedure: conventional surgery
Procedure: neoadjuvant therapy

First Posted Date: 2006-09-21

Last Posted Date: 2016-09-28

Lead Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Target Recruit Count: 38

Registration Number: NCT00379015

Locations: 🇯🇵
Niigata Cancer Center Hospital, Niigata, Japan
🇯🇵
Shikoku Cancer Center, Matsuyama-shi, Ehime, Japan
🇯🇵
National Kyushu Cancer Center, Fukuoka-shi, Fukuoka, Japan

and more 2 locations

Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia
Acute Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions: Device: Miltenyi reagent system
Other: FILGRASTIM (G-CSF)
Drug: Fludarabine
Drug: Cyclosporine
Drug: Cyclophosphamide

First Posted Date: 2006-09-20

Last Posted Date: 2021-06-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 116

Registration Number: NCT00378534

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy